Among women with early stage breast cancer, genetic variation of a certain enzyme appears to be associated with clinical outcomes for women treated with tamoxifen, according to a study in the October 7 issue of JAMA. "Tamoxifen has been the gold standard for the last 25 years for endocrine treatment of breast cancer.
More...